Evaluation of Immunohistochemical Expression of Survivin and its Correlation with qRT-PCR Results as a Useful Diagnostic Marker in Gastric Cancer.

Gastric cancer Immunohistochemistry Reverse transcriptase polymerase chain reaction Scoring system Survivin

Journal

Iranian journal of public health
ISSN: 2251-6093
Titre abrégé: Iran J Public Health
Pays: Iran
ID NLM: 7505531

Informations de publication

Date de publication:
Feb 2024
Historique:
received: 06 01 2023
accepted: 14 03 2023
medline: 19 6 2024
pubmed: 19 6 2024
entrez: 19 6 2024
Statut: ppublish

Résumé

Today, survivin is known as one of the most specific cancer proteins; provide unique and practical study opportunities. Clinical value of survivin in gastric cancer (GC) is not yet appointed. To establish the expression level of survivin and its diagnosis value in Iranian patients with GC, we evaluated the association of survivin expression with clinicopathologic factors. Overall, 60 matched-normal controls with 60 GC samples including 30 cases with evidence of metastasis at time of our study and 30 cases without evidence of metastasis were recruited, in Tehran, Iran during 2008 to 2018. Survivin expression was evaluated by quantitative Real-time polymerase chain reaction (qRT-PCR) and immunohistochemistry (IHC) study. Increased expression of survivin at mRNA and protein levels was found in 86.7% and 71.6% of cases, respectively. Evidence indicated a significant difference in survivin mRNA expression level between tumor and nontumoral (marginal) tissues ( This data could be supportive of using survivin as a useful diagnostic marker in GC. Although, more research is needed in this area.

Sections du résumé

Background UNASSIGNED
Today, survivin is known as one of the most specific cancer proteins; provide unique and practical study opportunities. Clinical value of survivin in gastric cancer (GC) is not yet appointed. To establish the expression level of survivin and its diagnosis value in Iranian patients with GC, we evaluated the association of survivin expression with clinicopathologic factors.
Methods UNASSIGNED
Overall, 60 matched-normal controls with 60 GC samples including 30 cases with evidence of metastasis at time of our study and 30 cases without evidence of metastasis were recruited, in Tehran, Iran during 2008 to 2018. Survivin expression was evaluated by quantitative Real-time polymerase chain reaction (qRT-PCR) and immunohistochemistry (IHC) study.
Results UNASSIGNED
Increased expression of survivin at mRNA and protein levels was found in 86.7% and 71.6% of cases, respectively. Evidence indicated a significant difference in survivin mRNA expression level between tumor and nontumoral (marginal) tissues (
Conclusion UNASSIGNED
This data could be supportive of using survivin as a useful diagnostic marker in GC. Although, more research is needed in this area.

Identifiants

pubmed: 38894824
doi: 10.18502/ijph.v53i2.14931
pii: IJPH-53-462
pmc: PMC11182479
doi:

Types de publication

Journal Article

Langues

eng

Pagination

462-471

Informations de copyright

Copyright© 2024 Fanaei et al. Published by Tehran University of Medical Sciences.

Auteurs

Khadijeh Fanaei (K)

Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran.

Fereshteh Ameli (F)

Department of Pathology, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.

Iman Salahshourifar (I)

Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran.

Shiva Irani (S)

Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran.

Mohsen Esfandbod (M)

Department of Hematology and Oncology, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.

Classifications MeSH